Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 23, 2018

View Archived Issues

Nailin approved in Japan for onychomycosis

AnGes submits application for marketing approval of HGF gene therapy in Japan

EC extends approval of Adcetris to include cutaneous T-cell lymphoma

Eureka Therapeutics closes series D financing round to advance lead candidate

Charcoal-delivering DAV-132 protects gut microbiome from antibiotic residues

BMS's Yervoy approved in E.U. for melanoma in pediatric patients

EMA committee gives positive opinion on orphan drug status for OMS-721

Phase III studies of reslizumab in eosinophilic asthma miss primary endpoints

Novartis completes tender offer for Advanced Accelerator Applications

BioCryst Pharmaceuticals and Idera Pharmaceuticals enter merger agreement

Imara initiates proof-of-concept phase II study of IMR-687 in sickle cell anemia

Board recommends continuation of Cynata Therapeutics' phase I study of CYP-001

New data suggest potential of once- or twice-weekly dosing of glepaglutide for short bowel syndrome

FDA grants fast track designation to SOBI-003 and accepts IND for first-in-human study

Genfit launches pediatric NASH program with elafibranor

Sucrose non-fermenting related kinase identified as a target for treating obesity

Phase IIIb trial of Aimovig meets endpoints in treatment-failure patients with episodic migraine

Venenum Biodesign discovers G-protein coupled bile acid receptor 1 agonists

Myeloperoxidase/eosinophil peroxidase inhibitors patented by Bristol-Myers Squibb

Jeil Pharmaceutical synthesizes novel H(+)/K(+) ATPase inhibitors

New lysyl-tRNA synthetase/laminin receptor interaction inhibitors patented by Yuhan

Regeneron synthesizes novel anti-GITR antibodies

Medeor Therapeutics awarded funding for phase III study of MDR-101

Pulmatrix cleared to begin first-in-human study of Pulmazole in U.K.

Celgene to acquire Juno Therapeutics

AP-202 shows promise as an agent for nicotine addiction

Nymox reports 5-year results from fexapotide triflutate study

Agenus launches AGEN-1884/AGEN-2034 combination study

Athenex reports results from two clinical studies of Oraxol